EVALUATION OF PITUITARY GONADOTROPINS, TESTOSTERON AND PROLACTIN PLASMA LEVELS IN PROSTATIC CANCER PATIENTS TREATED WITH FUGEREL
Article published in Urologia Polska 1996/49/3.

authors

Janusz Darewicz, Jerzy Badyda, Barbara Darewicz, Eugeniusz Malczyk: Z Kliniki Urologii Akademii Medycznej w Białymstoku
Kierownik Kliniki: doc. dr hab. med. J. Darewicz

The paper presents a group of twenty prostate cancer patients treated with Fugerel

during 6 weeks period. In all pateints were observed prominent decrease of complaints

and increase of the testosteron, LH, FSH and prolactin plasma levels. The authors

consider the increas of the hormonals levels as a signal of Fugerel profitable

effectiveness.

(1) Aulitzky W., Frick J., Joos H:. Inhibition of LHRH analogue induced testosterone
surge by blockade of androgen receptors. J. Urol., 1987, 137, 256.
(2) Bruchovsky N., Chapdelaine A., Neuman F.: regulation of androgen action. The
Proceedings of an International Symposium, Montreal 1984.
(3) Neumal F, Radmaier A., Bormacher K:. Hormonal of advanced prostate cancer.
Diesbach Verlag, 1989.
(4) Sogani P. C. Yuigawala M. R, Whitmore W. F, jr.: Experience with Flutamide in
patients with advanced prostatic cancer without prior aedocrine therapy. Cancer
1984,54,744.
(5) Winfield H., Trachtenberg J.: A Comparison of powerful luteininizing hormone re-
leasing hormone analogue and estrogen in the treatment of advanced prostatic can-
cer. J. Urol, 1984, 131, 1107.